Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

AMF Regulated Information

AMF Documents
AMF Press Releases

AMF Documents
AMF Press Releases

AMF Documents

Search Filings

Found 191 Results

Page 5 of 20« First «...3 456 7...10 20...»Last »

May 17, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2021

April 28, 2021

AGM 2021 – Total Number of Voting Rights and Existing Number of Shares

April 2, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021

March 17, 2021

DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document

March 17, 2021

March 12, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021

March 11, 2021

DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments

February 11, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2021

January 5, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2020

December 15, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020

Page 5 of 20« First «...3 456 7...10 20...»Last »

Latest AMF Press Releases

January 6, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

July 28, 2025

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

June 11, 2025

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

View All Press Releases

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top